|Bid||48.00 x 800|
|Ask||0.00 x 800|
|Day's Range||60.14 - 63.00|
|52 Week Range||43.27 - 86.58|
|Beta (3Y Monthly)||1.59|
|PE Ratio (TTM)||21.49|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shares of Akcea Therapeutics Inc. sank 10% in morning trade Monday, after the biopharmaceutical company three of its top executives were leaving the company, including Chief Executive Paula Soteropoulos, effective immediately. The others leaving were President Sarah Boyce and Chief Operating Officer Jeff Goldberg. The company, which is a majority-owned affiliate of Ionis Pharmaceuticals Inc. , said it named Damien McDevitt as interim-CEO. McDevitt was previously chief business officer at Ionis. Akcea said Michael Yang and Joseph Klein have jointed its board of directors. Ionis shares tacked on 0.3%. Over the past 12 months, shares of Akcea have tumbled 27.8%, Ionis have rallied 28.0% and the S&P 500 has gained 2.0%.
One of Akcea Therapeutics' biggest shareholders has instituted a shake-up at the Boston biotech, replacing longtime CEO Paula Soteropoulos and two other executives in a surprising move.
Biogen (BIIB) starts a DEVOTE study to investigate whether a higher dose of Spinraza can provide greater efficacy for treating patients with spinal muscular atrophy.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...
Ionis (IONS) out-licenses antisense medicines to Glaxo for treating chronic hepatitis B virus infection. Glaxo exercises its option to in-license the same. Shares fall.
Chairman and CEO of Ionis Pharmaceuticals Inc (30-Year Financial, Insider Trades) Stanley T Crooke (insider trades) sold 22,000 shares of IONS on 08/21/2019 at an average price of $71.52 a share. Continue reading...
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 96.30% and 16.49%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 6) Allakos Inc (NASDAQ: ALLK )(announced common stock offering) ...
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chairman & CEO of Ionis Pharmaceuticals Inc (30-Year Financial, Insider Trades) Stanley T Crooke (insider trades) sold 10,000 shares of IONS on 07/18/2019 at an average price of $70.25 a share. Continue reading...
John McCamant, editor of The Medical Technology Stock Letter, selected Ionis Pharmaceuticals (IONS) as a more conservative idea idea for 2019. The stock has risen 21%. Here's his latest update on this biotech firm.
It can be tough to pick winners in the world of pharmaceutical development, but Alexion, Regeneron, and Ionis offer investors good chances of strong returns.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Ionis Pharmaceuticals Inc NASDAQ/NGS:IONSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for IONS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding IONS are favorable, with net inflows of $3.29 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
In this article we are going to estimate the intrinsic value of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by taking...